Key Highlights

  • The Phase 2b RewinD-LB trial enrolled 159 dementia with Lewy bodies patients.
  • The study missed its primary cognitive endpoint in the intent-to-treat population.
  • Exploratory subgroup analyses showed potential signal trends in patients without Alzheimer's co-pathology and those with higher drug exposure.
  • Discontinuation due to adverse events occurred in 2.5% of treated patients versus 1.3% on placebo.

Primary Endpoint Not Met

CervoMed reported results from its Phase 2b RewinD-LB trial evaluating neflamapimod in 159 patients with dementia with Lewy bodies. The study did not meet its primary cognitive endpoint in the intent-to-treat population. However, exploratory subgroup analyses pointed to potential signal trends among patients without co-existing Alzheimer's pathology and among those with higher drug exposure levels, suggesting the treatment effect may vary across patient characteristics.

Biomarker Data and Next Steps

Biomarker and imaging data from the trial indicated that neflamapimod engaged its intended target, even though the overall cognitive endpoint was not achieved, which the company views as supportive of the drug's underlying mechanism. Safety data showed a discontinuation rate due to adverse events of 2.5% in the treatment group compared with 1.3% on placebo, a modest difference that suggests the drug was generally well tolerated. CervoMed said it plans to advance an optimized 100 milligram twice-daily dosing regimen based on these findings, while cautioning that clinical benefit has not yet been established.

Did the RewinD-LB trial meet its primary endpoint?

No. The Phase 2b trial missed its primary cognitive endpoint in the intent-to-treat population of 159 dementia with Lewy bodies patients.

What are CervoMed's next steps for neflamapimod?

CervoMed plans to advance an optimized 100 milligram twice-daily dosing regimen based on exploratory subgroup and biomarker findings, though clinical benefit has not yet been established.